Evolution of Systemic Therapy for Hepatocellular Carcinoma

Richard S. Finn, Andrew X. Zhu – 7 May 2020 – Despite being one of the leading causes of cancer death globally, hepatocellular carcinoma (HCC) has historically not been the focus of novel drug development. That has changed in the past several years, with the results from a number of hallmark phase 3 studies in advanced HCC. In HCC, immune‐oncology approaches have garnered much attention; there is still a need to better understand criteria for patient selection and to optimize combination strategies to maximize the potential of these approaches.

Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced Liver Disease: An Exploratory Meta‐Analysis

Francesco Violi, Annarita Vestri, Danilo Menichelli, Arianna Di Rocco, Daniele Pastori, Pasquale Pignatelli – 7 May 2020 – Direct oral anticoagulants (DOACs) have had a positive impact in preventing cardioembolic stroke in patients with atrial fibrillation (AF) who were associated with lower bleeding complications; however, data on subjects with concomitant advanced liver diseases (ALDs) are poor. This meta‐analysis evaluates bleeding and thromboembolic complications in patients with coexisting AF and ALD who were treated with DOACs or vitamin K antagonists (VKAs).

Subscribe to